- Home
- CWEN vs BHVN Comparison
CWEN vs BHVN Comparison
Compare CWEN & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- BHVN
- Stock Information
- Founded
- CWEN 2012
- BHVN 2013
- Country
- CWEN United States
- BHVN United States
- Employees
- CWEN N/A
- BHVN N/A
- Industry
- CWEN Electric Utilities: Central
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- CWEN Utilities
- BHVN Health Care
- Exchange
- CWEN Nasdaq
- BHVN Nasdaq
- Market Cap
- CWEN 3.1B
- BHVN 3.6B
- IPO Year
- CWEN 2013
- BHVN 2017
- Fundamental
- Price
- CWEN $25.97
- BHVN $39.56
- Analyst Decision
- CWEN Buy
- BHVN Strong Buy
- Analyst Count
- CWEN 7
- BHVN 13
- Target Price
- CWEN $30.86
- BHVN $63.00
- AVG Volume (30 Days)
- CWEN 751.0K
- BHVN 908.2K
- Earning Date
- CWEN 02-24-2025
- BHVN 02-27-2025
- Dividend Yield
- CWEN 6.34%
- BHVN N/A
- EPS Growth
- CWEN 124.49
- BHVN N/A
- EPS
- CWEN 1.04
- BHVN N/A
- Revenue
- CWEN $1,364,000,000.00
- BHVN N/A
- Revenue This Year
- CWEN $9.13
- BHVN N/A
- Revenue Next Year
- CWEN $7.39
- BHVN $197.13
- P/E Ratio
- CWEN $25.18
- BHVN N/A
- Revenue Growth
- CWEN 2.33
- BHVN N/A
- 52 Week Low
- CWEN $20.63
- BHVN $26.80
- 52 Week High
- CWEN $30.92
- BHVN $62.21
- Technical
- Relative Strength Index (RSI)
- CWEN 49.85
- BHVN 52.42
- Support Level
- CWEN $25.08
- BHVN $36.83
- Resistance Level
- CWEN $26.18
- BHVN $39.80
- Average True Range (ATR)
- CWEN 0.78
- BHVN 1.74
- MACD
- CWEN 0.12
- BHVN 0.23
- Stochastic Oscillator
- CWEN 69.01
- BHVN 71.77
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into conventional power generation, renewables and thermal divisions.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.